Clinical trials
Withdrawn Ovarian Neoplasms trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
44 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 2 |
| 2003 | 1 |
| 2005 | 3 |
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 5 |
| 2009 | 2 |
| 2010 | 2 |
| 2011 | 2 |
| 2012 | 3 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 3 |
| 2017 | 1 |
| 2018 | 3 |
| 2020 | 2 |
| 2021 | 2 |
| 2022 | 2 |
| 2023 | 2 |
| 2024 | 2 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Withdrawn | 44 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Gynecologic Oncology Group | 3 |
| M.D. Anderson Cancer Center | 3 |
| Roswell Park Cancer Institute | 3 |
| AstraZeneca | 2 |
| City of Hope Medical Center | 2 |
| Dana-Farber Cancer Institute | 2 |
| NYU Langone Health | 2 |
| National Cancer Institute (NCI) | 2 |
| University of Alabama at Birmingham | 2 |
| Abramson Cancer Center at Penn Medicine | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Ovarian Neoplasms | 44 |
| Fallopian Tube Neoplasms | 11 |
| Carcinoma, Ovarian Epithelial | 9 |
| Breast Neoplasms | 4 |
| Endometrial Neoplasms | 3 |
| Neoplasm Metastasis | 3 |
| Neoplasms | 3 |
| Recurrence | 2 |
| Triple Negative Breast Neoplasms | 2 |
| Uterine Cervical Neoplasms | 2 |
Trials
Showing 1 to 25 of 44. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.